Lee Bryan S, Gupta Preeya K, Davis Elizabeth A, Hardten David R
J Refract Surg. 2014 Aug;30(8):549-56. doi: 10.3928/1081597X-20140711-08.
To report the outcomes of photorefractive keratectomy (PRK) enhancement after LASIK for patients diagnosed as having hyperopic and myopic refractive errors.
In this retrospective case series at a single private practice in the United States, all patients undergoing PRK enhancement after LASIK were identified. Patients with visually significant cataract, non-plano targets, and follow-up of fewer than 226 days were excluded. The primary outcome measure was uncorrected distance visual acuity (UDVA) with secondary measures of corrected distance visual acuity (CDVA) and postoperative refractive error. Linear regression analysis was performed for actual versus targeted change in spherical equivalent.
Mean UDVA improved from 20/39 to 20/24 for hyperopes (n = 14; P < .002) and from 20/45 to 20/22 for myopes (n = 29; P < .0000001) after enhancement. All patients had a UDVA of 20/40 or better at their most recent follow-up visit. Fifty percent of hyperopes and 65.5% of myopes were 20/20 or better. The mean refractive error for hyperopes changed from +1.10 ± 0.71 (range: +0.13 to +2.25 diopters [D]) to +0.38 ± 0.66 D (range: -0.75 to +1.38 D) and from -1.21 ± 0.61 (range: -3.25 to -0.38 D) to +0.34 ± 0.45 D (range: -0.25 to +1.75 D) for myopes. The manifest refraction cylinder decreased from 0.84 to 0.46 D in hyperopes (P = .02) and from 0.64 to 0.26 D in myopes (P < .002). CDVA was maintained in both groups, with only one patient in each worse than 20/20. There was a nonsignificant trend toward less haze in the patients receiving mitomycin C (5.1% vs 25%, P = .14). Linear regression showed a tendency toward overtreatment in the myopic group.
PRK is safe and highly effective for patients who previously underwent LASIK and in whom the surgeon would prefer not to perform a flap-lift enhancement.
报告准分子激光原位角膜磨镶术(LASIK)后诊断为远视和近视屈光不正患者接受准分子激光角膜切削术(PRK)增效治疗的结果。
在美国一家私人诊所进行的这项回顾性病例系列研究中,确定了所有接受LASIK术后PRK增效治疗的患者。排除有明显视力障碍的白内障患者、非平面目标患者以及随访时间少于226天的患者。主要观察指标为未矫正远视力(UDVA),次要观察指标为矫正远视力(CDVA)和术后屈光不正。对等效球镜度的实际变化与目标变化进行线性回归分析。
增效治疗后,远视患者(n = 14;P <.002)的平均UDVA从20/39提高到20/24,近视患者(n = 29;P <.0000001)的平均UDVA从20/45提高到20/22。所有患者在最近一次随访时的UDVA均为20/40或更好。50%的远视患者和65.5%的近视患者视力达到20/20或更好。远视患者的平均屈光不正从+1.10±0.71(范围:+0.13至+2.25屈光度[D])变为+0.38±0.66 D(范围:-0.75至+1.38 D),近视患者的平均屈光不正从-1.21±0.61(范围:-3.25至-0.38 D)变为+0.34±0.45 D(范围:-0.25至+1.75 D)。远视患者的明显散光柱镜度从0.84降至0.46 D(P =.02),近视患者从0.64降至0.26 D(P <.002)。两组患者的CDVA均保持稳定,每组仅有1例患者视力低于20/20。接受丝裂霉素C治疗的患者出现角膜 haze 的趋势不显著(5.1%对25%,P =.14)。线性回归显示近视组有过度治疗的倾向。
对于先前接受过LASIK手术且手术医生不愿进行掀瓣增效治疗的患者,PRK是安全且高效的。